QualityDipStocks / Health Care · Pharmaceuticals
Rapport Therapeutics RAPP
Outside our quality screen, so we don’t track its dips. It’s 52% below its 52-week high.
Outside our quality screen. No fair value estimate for now: its free cash flow is negative.
- Fair value est.
- n/a
- Market Value
- forming
- Off 52-wk high
- −52%
- Risk vs market
- Market-likebeta 1.07
52-week range 9% of the way from its 52-week low to its high
Price $25.13
0 bullish · 3 bearish See why
Valuation
What we estimate it's worth, and how it ranks on value vs every stock we cover.
Fair value estimate
No estimate for RAPP: negative free cash flow. We’d rather show nothing than a made-up number.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 31 to Nov 2, 252 sessions). Beta = how much RAPP moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Moves about in line with the market, and its own price swings are 4.9× the S&P 500’s.
- Beta vs S&P 500
- 1.07
- Volatility
- 62% vs 13% SPY
- Correlation SPY
- 0.22
- Correlation QQQ
- 0.20
Valuation details
Fundamentals
The business itself: sales, profits, cash and debt, from SEC filings.
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 0 of 5
Nothing in our data makes a clear bull case right now.
Top bearish points 3 of 5
ValuationFree cash flow is negative (−$97M over the last 12 months), so there’s no cash-flow value under the price.
QualityDoesn’t pass our quality screen: no positive free cash flow; ROE under 12% and ROIC under 10%; no sales-growth data.
RiskReports earnings Nov 5 (consensus EPS ($1.21)): results can move the price sharply and reset Market Value.
All fundamentals
from SEC filings
No fundamentals for Rapport Therapeutics: Newly registered with the SEC: too few reported periods yet for trailing-12-month figures (latest 2026-06-30). We show nothing rather than guess.
The business
FCF $-0.1B
- Free cash flow, 12 months−$0.1B
- Free-cash-flow yield−6.7%
- Gross margin−109%
- Operating marginn/m
- Return on invested capital−146%
- Return on equity−40%
Chart & levels
Where the price is vs its key levels and trends.
Key levels
Every level vs today’s $25.13
- 52-wk lowlowest close, 1 year$22.50−10.5%
- PriceMon Nov 2 close$25.13you are here
- 52-wk highhighest close, 1 year$52.50+108.9%
Momentum & 52-week range
RSI 38 · 5 days −0.8%
Signals
Reversal signal setups, the public ledger and the next earnings date.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
Next report
Nov 5
- DateThu Nov 5
- Consensus EPS($1.21)
- Year-ago EPS($0.71)
- QuarterSep/2026
From Nasdaq’s earnings calendar. A report resets Market Value.
RAPP is outside our quality screen
One text when a published rule fires on one of the 332 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.
Voices & buzz
Who is talking about it, and how it compares with peers.
Who’s talking about it
Notable investors, executives, analysts and public figures on Rapport Therapeutics in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 3, 5:14 PM ET.
Compare with peers
Closest in size in Pharmaceuticals
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.